Featured Intelligence

Researchers reported results this summer from a trial of CAR T-cell therapy in severe lupus, using a cell therapy originally developed for leukemia. Nine patients received a single infusion of engineered cells targeting CD19, the marker carried by the

Blood tests that detect the protein changes of Alzheimer's disease have moved out of research settings and into ordinary clinical use, and the study that matters most is the one that put them in front of family doctors

In February the FDA approved labeling changes for menopausal hormone therapy products, removing the boxed warnings about cardiovascular disease, breast cancer and probable dementia that had sat at the top of those labels for more than two decades. Six products

Novartis released topline results this month from Lp(a)HORIZON, the first large outcomes trial of a drug designed to lower lipoprotein(a). The trial enrolled 8,323 people with elevated Lp(a) and established cardiovascular disease, and it did

A phase 2 trial published this year in Nature Medicine tested what happens when a muscle-preserving antibody is added to a GLP-1 drug. In 507 adults with obesity, the combination produced more total weight loss than the GLP-

A review of continuous glucose monitoring published this year in JAMA Internal Medicine reached a conclusion that sits awkwardly against how these devices are now marketed. In people who do not have diabetes, the authors found no scientific evidence that

In June, a company working on epigenetic reprogramming dosed the first patient in a phase 1 trial of a therapy called ER-100, aimed at two optic nerve conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The

In August the FDA granted accelerated approval to a one-time gene therapy for glycogen storage disease type Ia, a rare inherited disorder in which the body cannot release stored glucose properly and patients depend on carefully timed doses of

In May, the EPA proposed two changes to the federal drinking water rule for PFAS compounds. One would extend the compliance deadline for the limits on PFOA and PFOS by two years, to 2031, for eligible water systems. The other